MedTrace Logo

Efficacy Study of Intranasal Insulin to Treat Tobacco Abstinence Syndrome

NCT01781234 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2018-12-10

Study results available
· View outcomes & findings →

Summary

This study will evaluate safety and efficacy of intranasal insulin in abstinent smokers. Groups' (placebo vs. insulin) cognitive function and stress response will be compared.

Conditions

  • Tobacco Abstinence Syndrome

Interventions

DRUG

Intranasal Insulin

DRUG

Placebo

Sponsors & Collaborators

  • Ajna Hamidovic

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-08-31
Primary Completion
2016-05-31
Completion
2016-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01781234 on ClinicalTrials.gov